NCT05027425View on ClinicalTrials.gov

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

December 7, 2025

Study Completion Date

December 7, 2030

Conditions
Hepatocellular CarcinomaCirrhosisPortal Hypertension
Interventions
DRUG

Durvalumab

1500 mg IV, Q4W

DRUG

Tremelimumab

300 mg IV, 1 dose on day 1 of only the first cycle

PROCEDURE

Liver Transplant

minimum 72-day washout from the end of immunotherapy, patients will undergo liver transplant.

Trial Locations (3)

45267

University of Cincinnati, Cincinnati

63130

Washington University School of Medicine, St Louis

75235

Simmons Comprehensive Cancer Center UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

Davendra Sohal

OTHER